

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



IVD Medical Holding Limited

華檢醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1931)

**SUPPLEMENTAL ANNOUNCEMENT
CONNECTED TRANSACTION
FORMATION OF PARTNERSHIP**

Reference is made to the announcement (the “**Announcement**”) of IVD Medical Holding Limited (the “**Company**”) dated 3 August 2020 in relation to formation of partnership, which constituted a connected transaction of the Company under the Listing Rules. Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement, unless otherwise provided herein.

The Company would like to supplement the Announcement with additional information on Zhongmin Huiyuan under the section headed “Information about the Company and the Parties” on page 5 of the Announcement as follows:

Zhongmin Huiyuan

Zhongmin Huiyuan is owned indirectly as to approximately 30% by Shandong SASAC, as to approximately 30% by China Minsheng Investment Co., Ltd. (中國民生投資股份有限公司), an investment company in China, and as to approximately 40% by Ningbo Lingjun Management and Consulting Partnership (Limited Partnership)* (寧波領駿管理諮詢合夥企業(有限合夥)), a limited partnership established under the laws of the PRC, which is an investment vehicle and beneficially owned by three Chinese citizens, namely Ms. Zhang Shanshan, Ms. Wang Meinong and Mr. Cao Ziliang, each of which is principally engaged in financial investments and is a third party independent of the Company and the connected persons of the Company.

Zhongming Huiyuan commenced its operation in fund management since 20 January 2020, upon obtaining qualification as a registered fund manager accredited by the Asset Management Association of China (中國證券投資基金業協會). It is principally engaged in equity investment and investment management in health industry in China. As at the date of this announcement, in addition to the Partnership, Zhongming Huiyuan is managing three other funds with details set out below:

Name	Date of Establishment	Place of Establishment	Fund Size (RMB)	Investment Scope
Jiaxing Huizhi Investment Partnership (Limited Partner)	10 March 2020	PRC	10,700,000	Equity investments in companies focusing on research and development of IVD products
Jiaxing Huineng Investment Partnership (Limited Partner)	13 May 2020	PRC	10,700,000	Equity investments in companies focusing on research and development of IVD products
Jiaxing Huiling Investment Partnership (Limited Partner)	13 May 2020	PRC	10,060,000	Equity investments in companies focusing on research and development of pharmaceuticals

The historical return rates of the above three funds are not available as they are established in the course of year 2020 and their investments have not yet been realised and/or valued by reference to mark-to-market valuation.

Save as the above supplemental information, all other contents of the Announcement remain unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement.

** For identification purpose only*

By order of the Board of
IVD Medical Holding Limited
Ho Kuk Sing
Chairman and Executive Director

Hong Kong, 11 August 2020

As at the date of this announcement, the Board comprises three executive directors, namely, Mr. Ho Kuk Sing, Mr. Leung King Sun and Mr. Lin Xianya, three non-executive directors, namely, Mr. Chen Xingang, Mr. Yang Zhaoxu and Mr. Chan Kwok King, Kingsley and three independent non-executive directors, namely, Mr. Lau Siu Ki, Mr. Zhong Renqian and Mr. Leung Ka Sing.